Upcoming event

Tags

Abiraterone, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen deprivation therapy, Androgen pathway blockade, Androgen receptor inhibitor, Antiandrogens, Anticancer agents, ARCHES, Article of the Month, ASCO GU21, ASCO GU22, ASCO21, AUA21, BHC80, Biochemical recurrence, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, BRCA1, BRCA2, Castrate-resistanter, Castration-resistant, Chemotherapy, Clinical trial, Clinical trials, Cohort study, COVID-19, cSP, Deferred treatment, Diagnosis, Disease progression, Docetaxel, EAU21, EAU22, Emission-computed, EMUC21, EMUC22, End-to-side nerve grafting, Enzalutamide, Erectile dysfunction, Erectile function, ESMO21, ESMO22, ESOU Online, ESU Masterclass, ESU Masterclasses, External beam radiotherapy, Focal therapy, Frozen section, Fusion biopsies, Genomic classifier, Genomics, Guidelines, hormone-sensitive, HORRAD, HRQL, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Intensity-modulated radiotherapy, Local radiotherapy, Localised, Localized, Localized prostate cancer, Lymph node excision, Lymphadenectomy, Mapping, Mass spectrometry, Masterclass, Masterclasses, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, Mortality reduction, mp-MRI, MRI, Neoplasm staging, Nerve sparing, Next-generation sequencing, Nomogram, Noncastrate, Orchiectomy, Overdiagnosis, p53, Patient information, PCa21, Penile rehabilitation, PET/CT, Positron emission tomography, Precision medicine, Pretreatment risk stratification, Pretreatment tables, Primary tumor treatment, Prognosis, Prognostic model, Prostasomes, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, ProtecT trial, Proteomics, PSA, PSA flare, PSA kinetics, PSA screening, PSMA PET/CT, PTEN, Quality of life, Radiation therapy, Radical prostatectomy, Randomized prospective trial, Randomized trial, Randomized trials, Rapid metastasis, Rb, RB1, Receptors, Risk stratification, RNA splicing, Robotic prostatectomy, Robotic surgery, Robotic Urology, Robotics, Salvage therapy, Screening, Sentinel lymph node, Sexual quality of life, SREs, SRRM4, STAMPEDE, Stereotactic body radiotherapy, Surgical margins, Surgical video, Surgical videos, Systematic biopsy, Systematic review, Targeted Biopsy, TITAN, TP53, Transcriptome, Transperineal template biopsy, Tumor suppressor genes, Ultrasensitive PSA, Urinary incontinence, Urological surgery, Urowebinar, WCRF/AICR CUP, Webinar, Wnt, Zoledronic acid
Show all

The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells

J Urol. , Volume 193, Issue 2, February 2015, Pages 690-698

Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies

Am J Clin Nutr., Volume 101, Issue 1, January 2015, Pages 87-117

Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)

European Urology, Volume 67, Issue 4, April 2015, Pages 673-679

The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer

European Urology, Volume 66, Issue 4, October 2014, Pages 646-652

Relationships Between Times to Testosterone and Prostate-Specific Antigen Rises During the First Off-Treatment Interval of Intermittent Androgen Deprivation are Prognostic for Castration Resistance in Men With Nonmetastatic Prostate Cancer

Clin Genitourin Cancer., Volume 13, Issue 1, February 2015, Pages 10-16

PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer

Clin Genitourin Cancer, Volume 13, Issue 1, February 2015, Pages 39-43

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis

J Immunol Res.

Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy

J Clin Oncol

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials

Ann Oncol., Volume 26, Issue 4, April 2015, Pages 743-749

Long-term Safety and Antitumor Activity in the Phase 1–2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer

European Urology, Volume 68, Issue 5, November 2015, Pages 795-801

Pilot Validation Study of the European Association of Urology Robotic Training Curriculum

European Urology, Volume 68, Issue 2, August 2015, Pages 292-299

Associations between PSA kinetics and cause-specific mortality in patients with localised prostate cancer managed observationally: A sub-group analysis of the SPCG-6 study

European Urology Supplements, Volume 2, Issue 14

PreviousNext